Physician profile
Jonathan Hewett
NPI 1063696011
$11,328.50
in general payments reported to CMS, 2019-2025
31 companies · $1,114 in 2025
The $1,114 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,813 · 2020: $155 · 2021: $1,067 · 2022: $2,365 · 2023: $2,163 · 2024: $1,652 · 2025: $1,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,929.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,929.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,338.78 | 2019-2025 | Esprit, Supera, Jot Dx |
| Inari Medical, INC. | $2,337.55 | 2021-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Novartis Pharmaceuticals Corporation | $1,233.58 | 2021-2025 | |
| Medtronic, INC. | $1,068.24 | 2021-2025 | Micra, Linq II, Onyx Frontier |
| Boston Scientific Corporation | $754.70 | 2019-2025 | Avvigo Guidance System, General - Stents, Cds - Mct/Cem Monitoring |
| Amgen INC. | $407.08 | 2020-2025 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $285.93 | 2020-2025 | Eliquis, Camzyos |
| Pfizer INC. | $213.45 | 2022-2024 | |
| Novo Nordisk INC | $211.27 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Stryker Corporation | $206.56 | 2025 | Flowtriever, Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Alnylam Pharmaceuticals INC. | $202.43 | 2022-2025 | Onpattro |
| Astrazeneca Pharmaceuticals LP | $166.29 | 2020-2025 | Farxiga, Wainua |
| Abiomed | $149.88 | 2022-2023 | Impella |
| Angiodynamics, INC. | $102.03 | 2022-2025 | Alphavac, Auryon Laser System 100-120 Vac |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $96.46 | 2020-2024 | Lifevest |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endologix LLC | $84.60 | 2024 | Torus Stent Graft System, Endocross Device |
| Cardiva Medical, INC. | $61.61 | 2019-2025 | Optowire |
| Janssen Pharmaceuticals, INC | $57.82 | 2020-2022 | |
| Penumbra, INC. | $54.03 | 2024-2025 | Indigo System |
| Regeneron Healthcare Solutions, INC. | $48.79 | 2022-2023 | Praluent, Evkeeza |
| Merck Sharp & Dohme LLC | $45.74 | 2022-2023 | Verquvo |
| Kiniksa Pharmaceuticals, LTD. | $35.78 | 2023 | Arcalyst |
| Edwards Lifesciences Corporation | $32.32 | 2022-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Thrombolex, INC. | $21.50 | 2024 | Bashir Endovascular Catheter |
| Cordis US Corp. | $19.11 | 2025 | Mynx Control Venous |
| Biotronik INC. | $17.26 | 2019 | |
| Silk Road Medical, INC. | $17.14 | 2022 | |
| Bridgebio Pharma, INC. | $16.91 | 2025 | Attruby |
| La Jolla Pharmaceutical Company | $15.13 | 2022 | |
| Cardiovascular Systems INC. | $15.01 | 2019 | |
| Medtronic Vascular, INC. | $11.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Hewett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.